Can Oxytocin Treat Postpartum Depression? A Systematic Review Finds Mixed Results

Across 6 RCTs involving 195 women, oxytocin's effects on postpartum depression were mixed. For emotion: one trial showed oxytocin alleviated depressive mood, two showed no effect (though one found reduced negative thoughts in healthy mothers), and one actually showed oxytocin worsened depression. For cognition: four trials generally found oxytocin enhanced postpartum women's perception of their relationship with their infants. The review concluded that oxytocin may improve mother-infant cognitive bonding but its effects on depressive mood remain uncertain and contradictory.

Systematic review of randomized controlled trials. Databases searched: PubMed, Web of Science, Cochrane Library, and EmBase from inception through April 2022. Six RCTs meeting inclusion criteria were analyzed qualitatively, with effects categorized into emotional outcomes and cognitive outcomes.

Postpartum depression affects roughly 10-15% of new mothers and can severely impair mother-infant bonding and child development. Since oxytocin is naturally released during breastfeeding and skin-to-skin contact, it seemed like a logical therapeutic target. This review reveals a more nuanced reality: oxytocin may help mothers perceive their relationship with their baby more positively, but it doesn't reliably improve depressive mood — and in one case, actually worsened it.

Oxytocin has been called the 'love hormone' and widely assumed to have broadly positive effects on social bonding and mood. This review adds to a growing body of evidence showing that exogenous oxytocin's effects are far more complex and context-dependent than the popular narrative suggests. In some social contexts, oxytocin can actually increase negative emotions. For postpartum depression specifically, the research base remains too small and contradictory to draw conclusions, leaving this as a hypothesis that hasn't been confirmed.

Very small total sample size (195 women across 6 studies). The review could not perform a meta-analysis due to heterogeneity in outcomes and measurements across studies. Different oxytocin doses, routes, and timing were used across trials. The finding that oxytocin worsened depression in one trial raises safety concerns that need further investigation. Only studies through April 2022 were included.